About this item:
695 Views | 616 Downloads
Author Notes:
Author correspondence: H Jean Khoury, 1365 Clifton Road NE, Suite C1152, Atlanta, GA 30322, USA. Phone: 1-404-778-3932; Fax: 1-404-778-4755; Email: hkhoury@emory.edu
The authors report no conflict of interest in this work.
Subject:
Keywords:
- dasatinib
- resistant CML
- outcomes
Efficacy of dasatinib for the treatment of intractable chronic myeloid leukemia
Abstract:
Dasatinib (DAS) is a well tolerated oral dual SRC inhibitor with remarkable activity against all phases of imatinib-resistant chronic myeloid leukemia (CML). This paper focuses on the activity of DAS in intractable CML, and reviews outcomes of patients enrolled on DAS clinical trials. Safety and tolerability as well as practical tips for management of side-effects, and drug interactions are included.
Copyright information:
© 2010 Lima et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
This is an Open Access work distributed under the terms of the Creative Commons Attribution-Noncommercial 3.0 Unported License (http://creativecommons.org/licenses/by-nc/3.0/).
